Biodistribution studies showed that EGFP transgene delivery was reduced by 35-100% in liver, spleen, kidney, lung and thymus by the modified virus, while 98% of the transgene was delivered to IL-2R + tumors. In conclusion, the modification of NDV by the bispecific protein does not compromise severely the efficiency of gene delivery into IL-2R-positive tumors, but greatly reduces viral gene expression in IL-2R-negative tumors and in normal tissues.
Introduction
Newcastle Disease Virus (NDV), an avian negative-strand RNA virus of the family Paramyxoviridae, has characteristics which are very attractive for cancer therapy (1) (2) (3) . First, it shows tumor selective replication. Integral to the life cycle of all RNA viruses is the formation of double-strand RNA (dsRNA). dsRNA activates Toll-like receptor 3 and a spectrum of cellular defense mechanisms including the activation of RNA binding protein kinase (PKR) and the release of interferon ·/ß (4-6). Since tumor cells are frequently defective in their PKR signaling and interferon response pathways, they are relatively permissive for infection by RNA viruses. Second, its replication occurs in the cytoplasm of host cells and thus avoids potentially deleterious interactions with the genomic DNA. Third, reverse genetics techniques allow the modification of the viral RNA genome. Several recombinant NDV carrying transgenes, such as enhanced green fluorescent protein (EGFP) or human secreted alkaline phosphatase were generated (7) (8) (9) . Fourth, clinical applications of this virus are numerous. They are mainly based on two strategies. One is exploiting the immune stimulatory properties of NDV in the form of autologous tumor cell vaccine (ATV-NDV) to treat solid tumors. Clinical studies based on this strategy revealed significant improvement of patient survival (10) (11) (12) (13) . Another clinical application makes use of the oncolytic properties of some NDV strains (14, 15) .
Two main drawbacks limit the use of NDV in vivo. First, NDV binds to every cell, whether it is a normal or a tumor cell since the sialic acid-containing receptors for NDV are ubiquitously expressed on cell surfaces. Although NDV shows a preferential replication in tumor cells, its binding to normal cells might compromise its therapeutic effect and cause side effects when administered systemically in vivo. Second, in vivo administration of very high doses of NDV could produce toxic side effects.
To avoid the binding of NDV to normal cells and to selectively target it to tumor cells, we suggest to modify its properties by adding a linker molecule to its surface. We have previously shown in vitro that, by doing so, a recombinant NDV could be retargeted selectively to marker-defined tumor cells (16, 17) . For this, we pre-incubate the virus with a specially designed recombinant bispecific fusion protein (·HN-IL-2). As described before, ·HN-IL-2 binds to the HN molecule of the virus, thereby neutralising it, and to the IL-2 receptor (IL-2R), which is used as a tumor marker. Thus the protein assures the selective binding of the virus to the targeted tumor cells.
In this study, we investigated ex vivo and in vivo the delivery of genes to tumor and normal tissues via such a modified NDV vector.
Materials and methods

Cells, antibodies and bispecific fusion protein.
The metastatic mouse tumor cell line p11-R-Eb was obtained after i.p. passages of the non-metastatic Eb lymphoma cells into DBA/2 mice (18) . The cells were propagated in RPMI-1640 medium supplemented with 10% foetal calf serum (FCS) at 37˚C in a humidified atmosphere of 5% CO 2 .
Polyclonal rabbit anti-NDV serum was prepared by immunizing rabbit four times s.c. with 40000 HU/ml NDVUlster mixed 1:1 with incomplete Freund's adjuvant. Preimmune serum and the antiserum were heat-inactivated (for 45 min at 56˚C), aliquoted and stored at -20˚C.
The bispecific fusion protein ·HN-IL-2 was constructed by fusion of a single-chain antibody cloned from a neutralizing HN specific hybridoma linked to the human cytokine IL-2 as described previously (16) .
Recombinant NDFL-EGFP. The recombinant NDFL-EGFP was derived genetically from non-lytic strain NDV-LaSota by reverse genetics as described previously (7, 16, 19) . The virus was propagated in embryonated chicken eggs, harvested from the allantoic fluid, purified by ultracentrifugation and cryopreserved in aliquots at -70˚C. The virus was quantified by a hemagglutination assay. One hemagglutination unit (HU) is defined as the smallest virus concentration leading to visible sheep erythrocyte agglutination.
In vitro infection of tumor cells with NDV.
Cell suspensions were washed twice with FCS-free RPMI-1640 medium and 1x10 6 cells were incubated with 10 HU of NDV or the same doses of modified NDV/·HN-IL-2 in a final volume of 100 µl for 1 h at 37˚C in a CO 2 incubator. During the incubation, cells were shaken every 15 min. The cells were then washed twice and further cultured for 24 h to allow for viral replication. Viral replication was then evaluated as EGFP fluorescence by flow cytometry and FACS data were analysed with CellQuest software (Becton-Dickinson, Heidelberg, Germany). 3, 3', labeling. To differentiate the Eb-M7 cells from the mouse peritoneal cavity cells, Eb-M7 cells were labelled with DiR (Molecular Probes, Leiden, The Netherlands) which has absorption and emission maxima in the near infrared region, where non-labelled cells are optically transparent. After 2 washes, the Eb-M7 cells were suspended at a density of 1x10 6 /ml in serum-free medium. Two µl of a 50 mg/ml stock solution of DiR was then added to the cells. After incubation for 15 min at 37˚C, the cells were washed twice with prewarmed serum-free medium.
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Ex vivo infection of tumor cells with NDV.
Pathogen-free DBA/2 mice were obtained from Charles River GmbH (Wiga, Germany) and kept under pathogen-free conditions at the DKFZ animal facilities (Heidelberg, Germany). All procedures involving mice was approved by the Animal Care and Use Committee of the German Cancer Research Center. DiRlabeled Eb-M7 cells (1x10 7 ) which were incubated either with 100 HU NDFL-EGFP or modified NDFL-EGFP/ ·HN-IL-2 for 1 h at 37˚C in vitro were then injected into the peritoneal cavity of mice that received whole body irradiation at 4.5 Gy 1 day before (the procedure here is named ex vivo modification). For the negative controls, NDV was replaced by PBS. After 24 h, cells in mouse peritoneal cavity were harvested by lavage technique using ice-cold PBS containing 5% FCS. The EGFP fluorescence of DiR-positive cells from the mouse peritoneal cavity was analysed by flow cytometry.
Intratumoral EGFP expression and immunohistochemistry (IHC) with NDV specific antibody. DBA/2 mice received s.c. implants of 5x10 6 syngeneic Eb-M7 (IL-2R· + ) or Eb-M7 (IL-2R· -) cells/100 µl PBS. One week after tumor cell implantation, NDFL-EGFP (100 HU/100 µl) or modified NDFL-EGFP/·HN-IL-2 (100 HU/100 µl) or an equivalent volume of PBS was injected intratumorally. To assess EGFP expression and virus replication, mice were euthanized at 1 or 24 h after virus injection. Tumors were harvested and fixed overnight in PBS containing 1.5% paraformaldehyde and 20% sucrose. Section (6-µm) were prepared from frozen tissues previously embedded in Tissue-Tek OCT Compound (Sakura Finetek Europe B.V., distributed by Vogel GmbH, Giessen, Germany). EGFP was visualized by fluorescence microscopy using an EGFP filter. Sections on slides coated with 3-triethoxysilylpropylamine (Sigma, Taufkirchen, Germany) were subjected to IHC using rabbit polyclonal anti-NDV serum (1:800 dilution), followed by chicken antirabbit Ig (H+L) Alexa Fluor  594 (1:400 dilution) (Molecular Probes). IHC sections were counterstained with 4',6-diamidino-2-phenylindole (DAPI).
Quantification of the in vivo EGFP expression by quantitative real-time reverse transcriptase-polymerase chain reaction (RRT-PCR). DBA/2 mice bearing either Eb-M7 (IL-2R·
+ ) or Eb-M7 (IL-2R· -) tumors were injected intratumorally either with 100 HU/100 µl of NDFL-EGFP or modified NDFL-EGFP/·HN-IL-2. Other DBA/2 mice bearing both Eb-M7 (IL-2R· + ) and Eb-M7 (IL-2R· -) tumors on their right and left flanks respectively were injected i.v. with 5000 HU of NDFL-EGFP or modified NDFL-EGFP/·HN-IL-2 into the tail vein. Twenty-four hours after injection, i.v. injected-mice were perfused transcardially through the aorta with DEPCtreated PBS until lung, liver and kidney turned pale. Tumors (IL-2R· + and IL-2R· -), liver, spleen, kidney, lung and thymus from i.v. injected-mice and tumors from intratumoral-injected mice were removed and immediately submerged in RNAlater RNA Stabilization solution (Qiagen GmbH, Hilden, Germany). RNA was extracted following the Qiagen RNeasy procedure for animal tissue (Qiagen). Then, first-strand cDNA was synthesized from it using the SuperScript TM II RNase HReverse Transcriptase (Invitrogen).
RRT-PCR was carried out using a Gene Amp  5700 Sequence Detection System (Applied Biosystems GmbH, Weiterstadt, Germany). Amplifications were run in separate tubes to illustrate relative quantitation of EGFP and normalized with an endogenous control, mouse ß-actin. Primers for EGFP (sense, 5'-ATC ATG GCC GAC AAG CAG AAG AAC-3'; antisense, 5'-GTA CAG CTC GTC CAT GCC GAG AGT-3') (20) and mouse ß-actin (sense, 5'-ACG GCC AGG TCA TCA CTA TTG-3'; antisense, 5'-AGG ATT CCA TAC CCA AGA AGG AA-3') were synthesized by the German Cancer Research Center. Each RRT-PCR was performed in a 25 µl reaction mixture containing 17.5 µl Master Mix (qPCR TM Core Kit for SYBR  Green I, Eurogentec, Köln, Germany), 300 nM of each primer for EGFP or 300 nM (sense) and 900 nM (antisense) for ß-actin. cDNA from PBS-treated mice was used as negative controls and was included in each set of experiments. A common threshold was set in the exponential phase of the PCR reactions to determine a specific threshold cycle (C T ) number for each sample. Comparative C T method was used to relatively quantify the EGFP expression.
Results
Cloning of Eb-M7 (IL-2R · + ) and Eb-M7 (IL-2R· -) cells.
To prove the principle of retargeted virus infection of tumors we decided to first select target positive and target negative tumor cell lines from the mouse lymphoma p11-R-Eb. This cell line contains IL-2R· positive and negative cells as revealed by staining with mouse mAb CD25-PE and FACS analysis (Fig. 1A) . After three rounds of sorting we were able to select a high IL-2R· expressing cell population (here called Eb-M7 IL-2R· + ) and a very low IL-2R·-expression cell population (here called Eb-M7 IL-2R· -). One hundred percent of Eb-M7 (IL-2R· + ) cells were positive for IL-2R· and the mean fluorescence intensity (FI) for IL-2R· was enhanced 3.5-fold in comparison to the parental p11-R-Eb cells. In contrast, the Eb-M7 (IL-2R· -) cells were completely negative for IL-2R· expression. Both cell populations were stable with regard to their expression of IL-2R over many culture passages. We first tested the effect of the bispecific fusion protein ·HN-IL-2 on the tropism of NDV. For that, 10 HU of NDFL-EGFP was pre-incubated with 12 µg/ml of ·HN-IL-2 for 1 h on ice. This modified virus was then used to infect p11-R-Eb, Eb-M7 (IL-2R· + ) and Eb-M7 (IL-2R· -) cells for 24 h at 37˚C. FACS analysis (Fig. 1B) showed that the relative EGFP expression was enhanced by a factor 3.2 in the Eb-M7 (IL-2R· + ) cell population in comparison to the parental p11-R-Eb cells. The relative EGFP expression in the Eb-M7 (IL-2R· -) cell population was only 2.6%. We conclude that virus binding and replication was improved in IL-2R· + cells and reduced considerably in the IL-2R· -cells.
Enhanced-retargeted gene transfer via NDFL-EGFP by
Retargeted gene expression in vivo after ex vivo infection.
To evaluate in vivo the retargeted gene transfer, DiR-labeled Eb-M7 (IL-2R· + ) or Eb-M7 (IL-2R· -) cells were infected ex vivo either with native or modified NDFL-EGFP. They were then given i.p. to DBA/2 mice which were Á-irradiated with 4.5 Gy one day before injection. After 24 h, peritoneal cells were harvested and DiR-positive cells were gated and analyzed by flow cytometry for EGFP expression. As shown 
Intratumoral NDV infection and EGFP expression in situ.
In order to test viral infection of tumor cells in vivo, DBA/2 mice bearing tumors of 0.5 cm diameter were injected intratumorally with 100 HU of native NDFL-EGFP or modified NDFL-EGFP/·HN-IL-2. Tumors were dissected at 1 or 24 h after virus application and subjected to immunohistochemistry (IHC) or to direct fluorescence microscopy. IHC revealed that tumor tissues from 1 h had virus bound to cell membranes (Fig. 3b) , while tumor tissues from 24 h had virus located in the cytoplasm (Fig. 3c) . After 24 h, viral replication in the tumor tissue caused in some areas tumor necrosis (high expression of viral antigens overlapping with an area of reduced cell nuclei, Fig. 3d) .
When analyzing the tumor sections by fluorescence microscopy, no EGFP fluorescence was observed in tumors harvested 1 h after virus inoculation (data not shown). In contrast, a strong EGFP fluorescence could be observed 24 h later. When using modified virus (NDFL-EGFP/·HN-IL-2) instead of NDFL-EGFP, target positive tumors expressed much more EGFP than target negative tumors (Fig. 4, right panels) .
Establishment of quantitative RRT-PCR for EGFP detection.
To achieve a high degree of sensitivity for the quantification of the EGFP signal, we established a real-time RT-PCR (RRT-PCR) assay. Mouse ß-actin served as endogenous control. Fig. 5a shows kinetics of RRT-PCR reactions obtained for the EGFP and ß-actin genes from Eb-M7 (IL-2R· + ) cells that were infected in vitro with NDFL-EGFP. Melting temperatures of dissociation curves (Fig. 5b) indicated that the amplicons were specific for EGFP and ß-actin, respectively. To determine whether the two amplicons have the same amplification efficiency, we analyzed how the difference in threshold cycles (C T ) obtained with EGFP and ß-actin (∆C T ) varied when the template was diluted. Theoretically, if the efficiencies of the two genes are approximately equal, the plot of log input amount versus ∆C T has a very low slope (<0.1). As shown in Fig. 5c , regression analysis of C T data for EGFP and ß-actin showed a horizontal line with a negligible absolute slope (0.09). This demonstrates that ß-actin can serve as a reliable reference to normalize the EGFP measurements.
In vivo determination of EGFP-mRNA by quantitative RRT-PCR after intratumoral virus inoculation.
To quantify transgene expression delivered by the modified recombinant NDFL-EGFP/·HN-IL-2 in comparison to the native NDFL- EGFP in tumor tissues, cDNA from whole Eb-M7 (IL-2R· + ) and Eb-M7 (IL-2R· -) tumors was synthesized by reverse transcription of RNA extracted from the tumors. EGFP expression in virus-treated tumors relative to PBS-treated tumors was calculated using the comparative C T method (Table I) (Table II) . We observed relatively high levels of EGFP mRNA in the lung, thymus, liver and spleen. Some EGFP mRNA could also be detected in tumors although at lower amounts. Compared to the native NDFL-EGFP, 98% of transgene was delivered to Eb-M7 (IL-2R· + ) tumors by modified NDFL-EGFP/·HN-IL-2, while 28% of transgene was found in Eb-M7 (IL-2R· -) tumors. Importantly, the EGFP-mRNA expression decreased significantly (by 35-100%) in normal organs when the virus NDFL-EGFP was modified with ·HN-IL-2.
Discussion
In this study we demonstrate that recombinant NDV, when modified by the bispecific fusion protein ·HN-IL-2, is an efficient vector for selective gene transfer into IL-2R-positive tumor cells both ex vivo and in vivo. The modification of NDV by the bispecific protein does not compromise severely the efficiency of gene delivery into IL-2R-positive tumors, but greatly reduces viral gene expression in IL-2R-negative tumors and in normal tissues.
Much attention has recently been focused on RNA viruses as vectors for tumor therapy, including measles virus, vesicular stomatitis virus (VSV), reovirus, and NDV. These are Table I . Quantification of the EGFP expression in tumors by RRT-PCR after intratumoral injection of native or modified NDFL-EGFP. - currently being developed as a novel class of anti-tumor agents either as a viral vector or as an oncolytic agent (21) (22) (23) . Our previous in vitro studies showed that lentogenic recombinant NDV with monocyclic replication properties can be retargeted to the IL-2R + human leukemia-like cell line, MT-2, by ·HN-IL-2, while the native tropism via the interaction between HN proteins and sialic-acid containing receptors was abolished (16) . Furthermore, we demonstrated that EGFP transgene expression was retargeted to MT-2 by NDFL-EGFP via ·HN-IL-2 ex vivo and that virus hemadsorption was inhibited by ·HN-IL-2 in vivo (17) . To prove the principle of virus retargeting in vivo, we first had to establish a model consisting of target-positive and target-negative tumor cell lines. For this purpose, we selected two cell populations, Eb-M7 (IL-2R· + ) and Eb-M7 (IL-2R· -) out of the parental p11-R-Eb cells. DBA/2 mice inoculated s.c. with 5x10 6 Eb-M7 (IL-2R· + ) and 1x10 7 Eb-M7 (IL-2R· -) cells developed similar tumors of 0.5-cm diameter on their flanks at 1 week. IHC staining demonstrated a similar difference of IL-2R· expression in vitro (data not shown).
Despite the fact that our bispecific fusion protein ·HN-IL-2 was constructed from the human IL-2 sequence, FACS analysis Several studies (20, 25, 26) employed real-time PCR to quantify EGFP or GFP transgene expression. To quantify EGFP expression in vivo, we also applied RRT-PCR in this study. Relative to native NDFL-EGFP, high amounts of the EGFP gene was transferred by modified NDFL-EGFP/ ·HN-IL-2 upon intratumoral inoculation of Eb-M7 (IL-2R· + ) tumors. RRT-PCR confirmed that only very low amounts of the EGFP gene was delivered by NDFL-EGFP/·HN-IL-2 to Eb-M7 (IL-2R· -) tumors. We showed before that NDFL-EGFP viral replication accompanied by EGFP expression can serve as a surrogate maker for virus replication (17) . Here, it is the first time that we evaluated the biodistribution of lentogenic NDV in tumor-bearing mice by RRT-PCR. By quantifying EGFP mRNA levels, we found that NDV can replicate in all the tested tissues (tumor, liver, spleen, lung, spleen and thymus). Among them, lung had the highest amounts of virus accumulation which may not be surprising after i.v. inoculation of the virus. The tissue tropism of the same strain NDFL-EGFP has been investigated in 14-day-old embryo- -------------------------------------------------nated chicken eggs by Al-Garib et al, who observed that lung and the chorioallantoic membrane were the initial target organs as determined by fluorescence microscopy (7). It was also reviewed by Morrison that avirulent NDV results largely in respiratory tract infections (27) . We have shown previously no replication of NDV in normal resting human T cells or in IL-2 pre-activated T cells, but replication in a broad spectrum of human and mouse tumor cells in vitro by flow cytometry (11) . Up to now no data exist about NDV replication in tissues of mammals. We show here that NDV to some degree can replicate in the digestive and respiratory tract of mice. Whether this is accompanied by cell death or tissue destruction is not known.
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After intravenous injection of the modified NDFL-EGFP/ ·HN-IL-2 into tumor-bearing mice, Eb-M7 (IL-2R· + ) tumors were the most prominent retargeted tissue. All normal organs were relatively refractory to this modified virus when compared to native NDFL-EGFP. These results demonstrate that, upon systemic delivery, recombinant NDV, when modified by a bispecific molecule i) can be retargeted to target positive tumors followed by retargeted transgene expression and ii) shows decreased side effects on normal tissues.
